Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors.

British journal of haematology - 1 Apr 2024

Madero-Marroquin Rafael, DuVall Adam S, Saygin Caner, Wang Peng, Gurbuxani Sandeep, Larson Richard A, Stock Wendy, Patel Anand Ashwin

Abstract excerpt

Data regarding the use of FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in acute lymphoblastic leukaemia (ALL) are lacking. We identified 14 patients with FLT3- or IDH1/2-mutated ALL. Three early T-cell precursor-ALL patients received FLT3 or IDH2 inhibitors. Patient 1 maintains a complete remission (CR) with enasidenib after intolerance to chemotherapy. Patient 2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme Inhibitors

Share to fms-Like Tyrosine Kinase 3

Share to Neoplasm Recurrence, Local

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Share to Pyrazines

Share to Triazines

Source

Identifiers

PMID: 38073116
DOI: 10.1111/bjh.19250

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors.PMID 38073116Read ↗

Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML.Semantic proximity Read ↗

Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemiaSemantic proximity Read ↗

Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients.Semantic proximity Read ↗

Short Course Venetoclax with standard chemotherapy is effective in Early T cell precursor acute lymphoblastic leukemiaSemantic proximity Read ↗

Relapsed/Refractory ETP‐ALL Successfully Treated With Venetoclax and Nelarabine as a Bridge to Allogeneic Stem Cell TransplantSemantic proximity Read ↗

Combined treatment with venetoclax, dasatinib, and FLT3 inhibitors for NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia: A pediatric case report.Semantic proximity Read ↗

Combination fedratinib and venetoclax has activity against human B-ALL with high FLT3 expressionSemantic proximity Read ↗

Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia.Semantic proximity Read ↗

Relapsed/refractory early T-cell precursor acute lymphoblastic leukemia was salvaged by venetoclax plus HAG regimen.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.